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Mutations in K-ras Codon 12
Detected in Plasma DNA Are Not an
Indicator of Disease in Patients with
Non-Small Cell Lung Cancer
To the Editor:
The demonstration that cell-free cir-
culating DNA detected in the plasma
of cancer patients is genetically iden-
tical to that of the primary tumor has
generated substantial interest, lead-
ing to 200 publications (http://
www.ncbi.nlm.nih.gov). Recently,
Wang et al. (1 ) reported in this jour-
nal that the method chosen for DNA
isolation might contribute signifi-
cantly to mutation detection (in their
case, K-ras mutations in the plasma
of patients with colorectal cancer).
Briefly, they recommended the use of
a modified guanidine/Promega
resin method (G/R) to isolate DNA,
affirming that this method enhances
assay sensitivity. We used the same
approach to detect K-ras mutations in
the plasma of patients with non-
small cell lung cancer (NSCLC) and
compared the Qiagen vs the G/R
method for isolation of circulating
DNA. We purified DNA from
plasma samples and cancer tissues
from 12 patients. The DNA in 2 ali-
quots of the plasma from each pa-
tient was isolated by the Qiagen
method (1, 2) and by the G/R
method according to Wang et al. (1 ).
Additionally, DNA was isolated by
the Qiagen method from matched
plasma and tissue samples (n  10
for each) and from 76 plasma-only
samples (36 from cancer patients and
40 from cancer-free volunteers) ac-
cording to Kopreski et al. (2 ). There
was no difference in the number of
K-ras mutations detected in the
plasma samples collected from pa-
tients (n 15; 41.7%) and from vol-
unteers (n  12; 30.0%; odds ratio 
1.6; P  0.21). In addition, when we
evaluated the presence of K-ras mu-
tations in the matched plasma and
neoplastic tissue samples, we ob-
served no correlation. Finally, when
we compared the results (K-ras sta-
tus) for DNA samples isolated from
plasma by the 2 different methods
with the results obtained for the
DNA isolated from tissue samples
(12 patients), we observed K-ras
codon 12 mutations in 2 different
tissue samples, whereas we detected
no mutations in plasma DNA iso-
lated with the Qiagen method and 2
mutations different from those iden-
tified in the corresponding tumor
tissue in the plasma DNA isolated
with the G/R method. The correla-
tion between controls and cases was
not significant (2  0.7; P 0.5). The
correlations between results ob-
tained for tissue DNA and for
plasma DNA isolated by the Qiagen
or G/R method also were not signif-
icant (P  0.4 and P  1.0, respec-
tively, nonparametric test for cases
vs samples), nor was the correlation
between the G/R and Qiagen isola-
tion methods (P  0.2).
These data show no relationship
between K-ras mutations found in
DNA from plasma and tumor tissue
from NSCLC patients. Our results do
not support the suggestion that K-ras
mutations detected in plasma DNA
are markers for tumor detection.
Ramirez et al. (3 ) analyzed K-ras
mutations (codon 12) in tumor and
paired serum DNA of 51 NSCLC
patients undergoing surgery and de-
tected mutations in 9 tumors and 12
serum samples. As suggested by
Gautschi and Ziegler (4 ), serum may
contain not only DNA of tumor ori-
gin, but also a variable fraction of
DNA derived from in vivo- and in
vitro-damaged hematopoietic cells.
Indeed, lymphocytes stimulated
with phytohemagglutinin or antigen
may release DNA (5 ). Furthermore,
human leukocytes stimulated by
neutrophil-derived hydroxyl radicals
may cause activation of K-ras codon
12 (6 ). In addition, inhaled particles
in exposed individuals can generate
reactive oxygen species that can acti-
vate K-ras (7 ). Moreover, K-ras muta-
tions are detected in neogenetic le-
sions of subpleural fibrotic lesions,
including ciliated bronchial epithe-
lium and metaplastic epithelium (8 ).
Because chronic inflammation may
be present in patients without cancer
as well as those with cancer (9 ), the
analysis of K-ras mutations in plasma
may be influenced by such factors.
Finally, as reported recently by Keo-
havong et al. (10 ), K-ras mutations
are frequently found in histologically
normal tissues near tumors, suggest-
ing that such mutations may repre-
sent an early event in the develop-
ment of lung cancer. K-ras mutations
thus may be present before clinically
detectable tumors. As a final point, it
is important to note that K-ras muta-
tions have been detected in patients
with ulcerative colitis, Crohn disease
(11, 12), and Helicobacter pylori-asso-
ciated chronic gastritis (13 ). We ob-
served K-ras mutation in 2 volunteers
diagnosed with chronic gastritis, in 1
patient with kidney failure, and in 2
who were heavy smokers.
In light of these observations,
plasma DNA assays for the detection
of mutations in codon 12 of K-ras do
not provide a reliable method to
screen populations for the somatic
mutations frequently found in neo-
plasms. Further confirmatory studies
are required.
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Denaturing HPLC-Based Assay for
Detection of ATRX Gene Mutations
To the Editor:
In 2003, we described (1 ) a broad-
range denaturing gradient gel elec-
trophoresis method for mutation
scanning of the entire open reading
frame and canonical splice sites of
the ATRX gene (OMIM 300032), a
zinc finger transcriptional regulator
undergoing X inactivation and prob-
ably involved in chromatin remodel-
ing, DNA methylation, and gene ex-
pression in mammalian development
(2, 3 ). Mutations affecting the ATRX
gene lead to the -thalassemia/men-
tal retardation syndrome (ATR-X
syndrome; OMIM 301040).
We now propose a simpler, rapid
mutational approach based on dena-
turing HPLC (DHPLC) (4 ), with
which we were able to confirm all of
the nucleotide variations described
in our first report (1 ) and to detect 5
other mutations in 7 of 15 unrelated
Italian patients with a clinical suspi-
cion of ATR-X syndrome. Segrega-
tion of the syndrome was sporadic in
all but 2 individuals. X-inactivation
status at the human androgen recep-
tor locus was tested in all patients’
mothers as described previously (5 ).
PCR primers (Table 1 of the Data
Supplement that accompanies the
online version of this letter at http://
www.clinchem.org/content/vol51/
issue7/) were designed to amplify all
35 exons and the consensus splicing
sites of the ATRX gene (Entrez Gene
ID 546). A total of 44 reactions were
performed at a single annealing tem-
perature (57 °C) with Optimase DNA
polymerase in 1	 buffer (both from
Transgenomic); exon 9 was amplified
as 10 overlapping fragments. Hetero-
duplex formation was obtained by
mixing together, denaturing, and
gradually reannealing equimolar
quantities of PCR products for pa-
tients and controls. DHPLC analysis
was performed with the WAVETM
3500HT System (Transgenomic).
Each crude PCR product (50 L) was
eluted by a 2.5-min run at 3 different
analysis temperatures, and the buffer
gradients were chosen as suggested
by the Navigator software (Trans-
genomic; Table 1 of the online Data
Supplement). Wild-type controls
were included in each run. For the
heterozygous elution profiles,
genomic DNA was reamplified with
the DHPLC primers and sequenced
using Big-Dye sequencing chemistry
(Applied Biosystems). No false-posi-
tive results were reported. In the 8
patients negative by DHPLC analy-
sis, direct sequencing failed to de-
tect any deleterious variations. The
DHPLC results are summarized in
Table 1 of the online Data Supple-
ment.
The new p.L195P (c.584TC) mu-
tation identified in this study was not
found in 200 apparently healthy fe-
males; moreover, this amino acid be-
longs to the zinc finger domain, was
conserved during evolution (data
not shown), and is segregated in a
3-generation pedigree with a classic
ATR-X phenotype and a skewed X-
inactivation status in carrier females.
The chromatograms for all muta-
tions found in our patients, including
those described in our first report (1 ),
are shown in Fig. 1.
Taking into account the time
needed to set up and run the PCR
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